Summary

The 7 major hypertriglyceridemia markets are expected to exhibit a CAGR of 3.52% during 2024-2034.

The hypertriglyceridemia market has been comprehensively analyzed in IMARC's new report titled "Hypertriglyceridemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hypertriglyceridemia is a medical condition characterized by abnormally high levels of triglyceride, which is a type of fat present in the bloodstream. In most cases, it does not cause any noticeable symptoms, and the disorder is often detected during routine blood tests. However, in some instances, individuals with very high triglyceride levels may experience indications like abdominal pain, nausea, vomiting, etc. They may also develop small, raised bumps on the skin called xanthomas, which can be a sign of hypertriglyceridemia. In rare cases, very high triglyceride levels can lead to acute pancreatitis, causing severe diarrhoea and high fever. The diagnosis of hypertriglyceridemia is generally made through a blood test that measures the concentration of triglycerides in the serum. A fasting lipid panel is usually recommended, where the patient is instructed to fast for at least 12 hours before the blood test. In addition to laboratory tests, a healthcare provider will typically evaluate a patient's medical history, family history, and lifestyle factors to determine the underlying cause of the ailment.

The increasing prevalence of several metabolic disorders, such as obesity, insulin resistance, type 2 diabetes, etc., is primarily driving the hypertriglyceridemia market. In addition to this, the rising incidence of numerous risk factors, including genetic predisposition, hyperthyroidism, use of certain medications like beta blockers, excessive alcohol consumption, kidney diseases, etc., is also bolstering the market growth. Moreover, the escalating usage of fibric acid derivatives, such as fenofibrate and gemfibrozil, for reducing triglyceride levels by up to 50% is creating a positive outlook for the market. These medications work by activating a receptor called peroxisome proliferator-activated receptor-alpha (PPAR-alpha) that regulates lipid metabolism in the liver. Besides this, the inflating utilization of bile acid sequestrants, including cholestyramine and colestipol, which lower triglyceride levels by binding to bile acids in the intestines, thereby preventing their absorption, is also augmenting the market growth. Furthermore, the emerging popularity of advanced lipoprotein testing, since it can provide detailed information about the size, density, and composition of lipoproteins in the blood as well as identify patients at higher risk of cardiovascular disease, is expected to drive the hypertriglyceridemia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the hypertriglyceridemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hypertriglyceridemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hypertriglyceridemia market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hypertriglyceridemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hypertriglyceridemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hypertriglyceridemia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the hypertriglyceridemia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hypertriglyceridemia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hypertriglyceridemia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of hypertriglyceridemia across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypertriglyceridemia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypertriglyceridemia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hypertriglyceridemia across the seven major markets?
What is the size of the hypertriglyceridemia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hypertriglyceridemia?
What will be the growth rate of patients across the seven major markets?

Hypertriglyceridemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hypertriglyceridemia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hypertriglyceridemia market?
What are the key regulatory events related to the hypertriglyceridemia market?
What is the structure of clinical trial landscape by status related to the hypertriglyceridemia market?
What is the structure of clinical trial landscape by phase related to the hypertriglyceridemia market?
What is the structure of clinical trial landscape by route of administration related to the hypertriglyceridemia market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Hypertriglyceridemia - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Hypertriglyceridemia - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Hypertriglyceridemia - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)

8 Hypertriglyceridemia - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Hypertriglyceridemia - Unmet Needs

10 Hypertriglyceridemia - Key Endpoints of Treatment

11 Hypertriglyceridemia - Marketed Products
11.1 List of Hypertriglyceridemia Marketed Drugs Across the Top 7 Markets
11.1.1 TriCor (Fenofibrate) - AbbVie/Fournier
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Zocor (Simvastatin) - Merck & Co
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Lipitor (Atorvastatin) - Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Crestor (Rosuvastatin) - AstraZeneca
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Vascepa (Ethyl eicosapentaenoic acid) - Amarin
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Hypertriglyceridemia - Pipeline Drugs
12.1 List of Hypertriglyceridemia Pipeline Drugs Across the Top 7 Markets
12.1.1 Volanesorsen - Ionis Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Omega 3 pentaenoic acid - Matinas BioPharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ISIS 678354 - Ionis Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ARO-APOC3 - Arrowhead Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 BIO89 100 - 89bio
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Hypertriglyceridemia - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Hypertriglyceridemia – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Hypertriglyceridemia - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hypertriglyceridemia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hypertriglyceridemia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hypertriglyceridemia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hypertriglyceridemia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hypertriglyceridemia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hypertriglyceridemia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hypertriglyceridemia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hypertriglyceridemia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hypertriglyceridemia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hypertriglyceridemia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hypertriglyceridemia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hypertriglyceridemia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hypertriglyceridemia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hypertriglyceridemia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hypertriglyceridemia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hypertriglyceridemia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hypertriglyceridemia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hypertriglyceridemia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hypertriglyceridemia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hypertriglyceridemia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hypertriglyceridemia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hypertriglyceridemia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hypertriglyceridemia - Access and Reimbursement Overview

16 Hypertriglyceridemia - Recent Events and Inputs From Key Opinion Leaders

17 Hypertriglyceridemia Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Hypertriglyceridemia Market – Strategic Recommendations

19 Appendix